COMPARISON
Octreotide vs Vasopressin
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Octreotide is authorised or registered in 10 and Vasopressin in 7 of the 10 registers read. Octreotide: highest phase Phase 4 (after approval). Vasopressin: highest phase Phase 4 (after approval). 9 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Octreotide | Vasopressin | |
|---|---|---|
| Registered trials differs | 344 clinicaltrials.gov · 2026-10-03 | 449 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VASOPRESSIN openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2025-06-30 ema · 2026-10-03 | Not checked no record of "authorisedOn" for vasopressin |
| EU withdrawn on differs | 2022-12-02 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for vasopressin |
| ATC code differs | H01CB02 ema · 2026-10-03 | Not checked no record of "atcCode" for vasopressin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Octreotide | placebo | Vasopressin | placebo |
|---|---|---|---|---|
| Diarrhoea | 46.2% | 31.7% | - | - |
| Oedema peripheral | 34.9% | 19.6% | - | - |
| Asthenia | 33.3% | 20.9% | - | - |
| Nausea | 30.8% | 21.2% | - | - |
| Fatigue | 29.8% | 27.7% | - | - |
| Rash | 28.8% | 14.1% | - | - |
| Decreased appetite | 28.5% | 15.2% | - | - |
| Hypertension | 26.5% | 19.4% | - | - |
| Dyspnoea | 25.9% | 9.1% | - | - |
| Anaemia | 24.3% | 9.1% | - | - |
Trial register Octreotide: 5 placebo-controlled trials; Vasopressin: 3. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Octreotide side effects · Vasopressin side effects
LEGAL STATUS
Approval in each country read
| Country | Octreotide | Vasopressin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
9 registered trials include both
| NCT07460908 | Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome COMPLETED · updated 2026-03-10 |
|---|---|
| NCT04028323 | Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903) UNKNOWN · updated 2021-08-17 |
| NCT04353193 | Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial. UNKNOWN · updated 2020-04-20 |
| NCT03846180 | Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage COMPLETED · updated 2019-07-05 |
| NCT00966355 | Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding COMPLETED · updated 2018-03-19 |
| NCT02119884 | Hemodynamic Effects of Terlipressin and High Dose Octreotide COMPLETED · updated 2016-06-13 |
| NCT02311608 | Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails UNKNOWN · updated 2014-12-08 |
| NCT00742339 | Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome TERMINATED · updated 2014-10-15 |
| NCT00534677 | The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed COMPLETED · updated 2007-12-05 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.